戴维医疗(300314) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥95,038,385.91, representing a 23.72% increase compared to ¥76,819,547.81 in the same period last year[7]. - Net profit attributable to shareholders for Q1 2021 was ¥22,002,474.79, a 50.60% increase from ¥14,610,045.15 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥18,242,713.93, up 49.24% from ¥12,223,828.75 in the previous year[7]. - The basic earnings per share for Q1 2021 was ¥0.08, reflecting a 60.00% increase from ¥0.05 in the same period last year[7]. - Total operating revenue for Q1 2021 reached ¥95,038,385.91, an increase from ¥76,819,547.81 in the previous period[42]. - Total operating costs amounted to ¥75,524,238.26, up from ¥62,308,026.36 year-over-year[43]. - Net profit for Q1 2021 was ¥22,002,474.79, compared to ¥14,610,045.15 in the same period last year, reflecting a growth of approximately 50.5%[44]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,047,146,214.60, a decrease of 6.68% from ¥1,122,135,774.65 at the end of the previous year[7]. - The net assets attributable to shareholders decreased by 2.22% to ¥932,322,466.63 from ¥953,519,991.84 at the end of the previous year[7]. - The company's total current liabilities decreased to CNY 112,317,170.94 from CNY 166,109,205.78, a reduction of approximately 32.39%[36]. - The total equity remained stable at CNY 463,322,466.63, unchanged from the previous reporting period[36]. - The company's total liabilities decreased to ¥72,616,840.20 from ¥115,738,318.46, a reduction of about 37.2%[40]. - The equity attributable to shareholders decreased to ¥962,774,262.99 from ¥993,917,020.12[40]. Cash Flow - The net cash flow from operating activities was negative at -¥53,198,078.06, worsening by 104.90% compared to -¥25,963,279.15 in the same period last year[7]. - Cash flow from operating activities showed a net outflow of CNY 53.20 million, a decline of 104.90% compared to the previous year[18]. - Operating cash flow net amount was -43,301,304.22 yuan, a decrease from -18,341,231.43 yuan in the previous period[54]. - Total cash inflow from operating activities was 61,603,820.39 yuan, down from 68,482,101.08 yuan year-over-year[54]. - Cash outflow from operating activities totaled 104,905,124.61 yuan, compared to 86,823,332.51 yuan in the previous period[54]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,279[10]. - The top three shareholders, Chen Zaihong, Chen Yunqin, and Chen Zaiwei, hold 24.69%, 21.12%, and 20.25% of the shares, respectively[10]. Market and Sales Performance - The revenue from the anastomosis and components series surged by 164.21% year-on-year, reaching CNY 32.32 million[20]. - The domestic market accounted for 81.52% of total revenue, with a 39.03% increase in domestic sales compared to the previous year[20]. - The company has no significant reliance on any single supplier or customer, with the top five suppliers and customers accounting for 21.66% and 18.70% of total purchases and sales, respectively[21]. Research and Development - The company is focusing on increasing R&D investment to enhance product technology and differentiation, aiming to improve brand recognition and market competitiveness[23]. - Research and development expenses for Q1 2021 were ¥8,869,999.84, compared to ¥7,723,364.00 in the previous year, showing an increase of approximately 14.9%[43]. - The company has committed to enhancing collaboration with end customers and research institutions to develop advanced and practical new products[23]. Investment Activities - The company’s investment activities generated a net cash inflow of CNY 87.61 million, a 248.58% increase from the previous year[18]. - Cash inflows from investment activities were 403,733,948.64 yuan, up from 334,625,527.39 yuan year-over-year[56]. - Cash outflow from investment activities was 315,165,450.00 yuan, down from 391,934,783.00 yuan in the previous period[56]. Other Financial Metrics - The weighted average return on net assets was 2.28%, an increase of 0.53% from 1.75% in the previous year[7]. - The company's gross profit margin improved due to better cost and expense control, alongside a favorable sales structure[19]. - The company reported a significant increase in accounts receivable, which rose by 40.06% to CNY 21.17 million due to increased credit limits for agents[17]. - The total sales expenses increased by 81.36% to CNY 15.85 million, primarily due to aggressive market expansion efforts by subsidiaries[18]. - The company experienced a decrease in operating profit to CNY 13,193,181.97 from CNY 16,633,138.82, indicating challenges in maintaining profitability[48]. Dividend and Cash Management - The company distributed dividends totaling 43,200,000.00 yuan during the period[56]. - The impact of exchange rate changes on cash and cash equivalents was 548,480.74 yuan[56]. - The first quarter report was not audited[58].